Romosozumab for the treatment of osteoporosis
10.1016/j.afos.2018.03.002
- Author:
Michael R MCCLUNG
1
Author Information
1. Oregon Osteoporosis Center, Portland, OR, USA. mmcclung.ooc@gmail.com.
- Publication Type:Review
- Keywords:
Romosozumab;
Sclerostin;
Osteoporosis;
Fracture risk;
Manuscript category
- MeSH:
Female;
Humans;
Osteoblasts;
Osteogenesis;
Osteoporosis;
Osteoporosis, Postmenopausal
- From:Osteoporosis and Sarcopenia
2018;4(1):11-15
- CountryRepublic of Korea
- Language:English
-
Abstract:
Romosozumab, a specific inhibitor of sclerostin, is a unique approach to therapy for postmenopausal osteoporosis and related disorders. The elucidation of sclerostin deficiency as the molecular defect of syndromes of high bone mass with normal quality, and the pivotal role of sclerostin as a mediator of osteoblastic activity and bone formation, provided the platform for the evaluation of inhibitors of sclerostin to activate bone formation. An extensive preclinical program and 2 large fracture endpoint trials with romosozumab, a sclerostin-binding antibody, have been completed. This review will highlight the results of those studies and describe the current status of romosozumab as a potential therapy for osteoporosis.
